Literature DB >> 34038019

EZ-ALBI score as a new prognostic predictor in hepatocellular carcinoma.

Shu-Yein Ho1,2,3, Po-Hong Liu3,4, Chia-Yang Hsu3,5, Chih-Chieh Ko3,6, Yi-Hsiang Huang3,6,7, Chien-Wei Su3,6, Cheng-Yuan Hsia3,8, Ping-Hsing Tsai2,9, Shih-Jie Chou2,9, Rheun-Chuan Lee3,10, Ming-Chih Hou3,6, Teh-Ia Huo2,3,9.   

Abstract

BACKGROUND: Liver functional reserve is a major prognostic determinant in patients with hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score is an objective method to assess the severity of cirrhosis in this setting. However, the calculation of ALBI score is complex and difficult to access in clinical practice. Recently, the EZ (easy)-ALBI score was proposed as an alternative biomarker of liver injury. We aimed to evaluate the prognostic role of EZ-ALBI score in HCC from early to advanced stages.
METHODS: A total of 3,794 newly diagnosed HCC patients were prospectively enrolled and retrospectively analyzed. Independent prognostic predictors were determined by using the multivariate Cox proportional hazards model.
RESULTS: The EZ-ALBI score showed good correlation with ALBI score (correlation coefficient: 0.965, p< 0.001). The correlation of EZ-ALBI score was highly preserved in different Child-Turcotte-Pugh (CTP) classification, treatment modality, and BCLC stage (correlation coefficients: 0.90-0.97). In the Cox multivariate analysis, age > 65 years, male, serum α-fetoprotein > 20 ng/mL, large or multiple tumors, total tumor volume > 100 cm3 , vascular invasion or distant metastasis, ascites, poor performance status, EZ-ALBI grade 2 and 3, and non-curative treatments were independently associated with increased mortality (all p< 0.05). Moreover, EZ-ALBI grade can stratify long-term survival in patients with different CTP class, treatment strategy and BCLC stage.
CONCLUSIONS: The EZ-ALBI score is an easy and feasible method to evaluate liver functional reserve. As a new prognostic biomarker in HCC, the predictive power of EZ-ALBI grade is independent across different cancer stage and treatment modality. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  EZ-ALBI score; hepatocellular carcinoma; prognosis

Year:  2021        PMID: 34038019     DOI: 10.1111/hepr.13671

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  1 in total

1.  Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.

Authors:  Prooksa Ananchuensook; Supachaya Sriphoosanaphan; Sirinporn Suksawatamnauy; Nipaporn Siripon; Nutcha Pinjaroen; Nopavut Geratikornsupuk; Stephen J Kerr; Kessarin Thanapirom; Piyawat Komolmit
Journal:  BMC Gastroenterol       Date:  2022-06-14       Impact factor: 2.847

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.